Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 8904 results

  1. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Withdrawn guidance

  2. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    This guidance has been updated and replaced by NICE technology appraisal guidance 713.

    Withdrawn guidance

  3. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

    Withdrawn guidance

  4. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Withdrawn guidance

  5. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

    Withdrawn guidance

  6. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Withdrawn guidance

  7. Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309)

    This guidance has been updated and replaced by NICE technology appraisal guidance 402.

    Withdrawn guidance

  8. The clinical effectiveness and cost effectiveness of sibutramine for obesity (TA31)

    This guidance has been replaced by NICE guideline CG43. 

    Withdrawn guidance

  9. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guidance

  10. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

    Withdrawn guidance

  11. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance

  12. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234)

    This guidance has been updated and replaced by NICE technology appraisal guidance 280.

    Withdrawn guidance

  13. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Withdrawn guidance

  14. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Withdrawn guidance

  15. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

    Withdrawn guidance